Systemic Inflammation and the Risk of Alzheimer's Disease and Dementia: A Prospective Population-Based Study

Article type: Research Article

Authors: Sundelöf, Johan^a | Kilander, Lena^a | Helmersson, Johanna^{c; d} | Larsson, Anders^b | Rönnemaa, Elina^a | Degerman-Gunnarsson, Malin^a | Basun, Hans^a | Lannfelt, Lars^a | Basu, Samar^{c; d; *}

Affiliations: [a] Department of Public Health and Caring Sciences/Geriatrics, Faculty of Medicine, Uppsala University, Uppsala, Sweden | [b] Uppsala University, Department of Medical Sciences, Uppsala University, Uppsala, Sweden | [c] Department of Public Health and Caring Sciences/Oxidative stress and Inflammation, Faculty of Medicine, Uppsala University, Uppsala, Sweden | [d] Center of Excellence-Inflammation, Uppsala University Hospital, Uppsala, Sweden

Correspondence: [*] Corresponding author: Dr. S. Basu, Department of Public Health and Caring Sciences/Oxidative stress and Inflammation, Uppsala Science Park, Dag Hammarskölds väg 14B, SE-751 85 Uppsala, Sweden. Tel.: +46 18 611 79 58; Fax: +46 18 611 79 76; E-mail: samar.basu@pubcare.uu.se.

Abstract: Inflammation is suggested to be involved in the pathogenesis of Alzheimer's disease (AD). Serum interleukin-6 (IL-6) and high sensitivity serum reactive protein C (hsCRP) as markers of systemic inflammation were analyzed at two examinations of the ULSAM-study, a longitudinal, community-based study of elderly men (age 70, n = 1062 and age 77, n = 749). In addition, serum amyloid protein A (SAA) and urinary prostaglandin F2α (PGF2α) metabolite levels were analyzed at age 77 in this cohort. Two serial samples (at ages 70 and 77) were available from 704 individuals. Using Cox regression analyses, associations between serum IL-6, hsCRP, SAA and PGF2α metabolite levels and risk of AD, any type of dementia (all-cause dementia) and non-AD dementia were analyzed. On follow-up (median, 11.3 years) in the age 70 cohort, 81 subjects developed AD and 165 subjects developed all-cause dementia. Serum IL-6, hsCRP, SAA, or PGF2α levels were not associated with risk of AD. At age 70, high IL-6 levels were associated with an increased risk of non-AD dementia (Hazard ratio 2.21 for above vs. below/at median, 95% confidence interval 1.23–3.95, p-value = 0.008). A longitudinal change in CRP or IL-6 levels was not associated with AD or dementia. In conclusion, Serum IL-6, hsCRP, SAA, and PGF2α levels are not associated with the risk of AD. High serum IL-6 levels may be associated with increased risk of non-AD dementia. Erratum in JAD20(2), p. 681.

Keywords: Alzheimer's disease, biomarkers, dementia, inflammation

DOI: 10.3233/JAD-2009-1126

Journal: Journal of Alzheimer's Disease, vol. 18, no. 1, pp. 79-87, 2009